Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05664243 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
A Phase 1 study of Glioblastoma, sponsored by In8bio.
- Active
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
- 5
- Study locations
NCT05664243: Active Phase 1 study of Glioblastoma, sponsored by In8bio.
NCT05664243 is a Phase 1 study of Glioblastoma that is active but no longer recruiting, run by In8bio. The registered enrollment target is 4 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (96% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05664243, a Phase 1 study of Glioblastoma, is active but no longer recruiting, sponsored by In8bio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
- 5
- Study locations
Study Summary
This multicenter, Phase 1b/2 study is being conducted to determine if the experimental cell therapy is safe, tolerable and can delay the return of cancer in patients with a newly diagnosed or recurrent glioblastoma multiforme (GBM) in combination with standard chemotherapy treatment temozolomide (TMZ). If there is a 25% or greater improvement in survival in this study then the therapy should be studied further.
Primary Outcome
Date of first dose to date of death by any cause
Conditions Studied
Interventions
- BIOLOGICAL Autologous genetically modified gamma-delta T cells
- BIOLOGICAL Allogeneic genetically modified gamma-delta T cells
Study Locations (5)
Ohio
- Cleveland Clinic - Cleveland
- Ohio State University Wexner Medical Center- James Cancer Center - Columbus
Alabama
- University of Alabama at Birmingham - Birmingham
Florida
- Moffitt Cancer Center - Tampa
Kentucky
- University of Louisville Hospital/James Graham Brown Cancer Center - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2023-09-08 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
What the registry record for NCT05664243 still lists
NCT05664243 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which Autologous genetically modified gamma-delta T cells is the first listed.
NCT05664243 lists 5 locations in 4 states (Ohio, Alabama, Florida).
Frequently Asked Questions
What is clinical trial NCT05664243 about?
NCT05664243 is a clinical study titled "A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma". This multicenter, Phase 1b/2 study is being conducted to determine if the experimental cell therapy is safe, tolerable and can delay the return of cancer in patients with a newly diagnosed or recurrent glioblastoma multiforme (GBM) in combination with standard chemotherapy treatment temozolomide (TM...
What is the current status of trial NCT05664243?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2023-09-08. Estimated completion is 2025-12.
What conditions does trial NCT05664243 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT05664243?
The interventions under investigation include: Autologous genetically modified gamma-delta T cells (BIOLOGICAL), Allogeneic genetically modified gamma-delta T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT05664243?
This trial is sponsored by In8bio, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05664243 being conducted?
This trial has 5 study locations across Alabama, Florida, Kentucky, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05664243's enrollment target sits among peer trials
4 198th of 199 higher than 2 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI